high mobility group box 3 pseudogene 10Genealiases: []
Q-omics provides the consensus-scored HMGB3P10 profile across patient tissues and cancer cell-line models. HMGB3P10 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, HMGB3P10 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, HMGB3P10 RNA expression shows 9,197 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, LUAD, and TGCT as cancer lineages where HMGB3P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P10 survival associations across molecular data types. HMGB3P10 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P10 RNA expression–survival associations across cancer types. High HMGB3P10 expression shows unfavorable associations in READ, LGG and LAML, but favorable associations in MESO, UCS and OV. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify READ as the clearest survival context for HMGB3P10 RNA expression.
This table summarizes HMGB3P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P10 shows lower tumor expression in LUAD, BRCA, LUSC, HNSC, KICH and UCEC. The LUAD box plot shows higher HMGB3P10 RNA expression in normal versus tumor tissue (log2 FC = −0.837, t-test p < 0.001).
This table shows molecular features associated with HMGB3P10 in patient tissues and cancer cell lines. In patient samples, HMGB3P10 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
